Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
09
2023
accepted:
03
10
2023
medline:
24
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic "window of opportunity". Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations. It focuses on genetic newborn screening and artificial intelligence-based tools which will be applied to a large European population of about 25.000 infants. The neonatal screening strategy will be based on targeted sequencing, while whole genome sequencing will be offered to all enrolled infants who may show early symptoms but have resulted negative at the targeted sequencing-based newborn screening. We will leverage artificial intelligence-based algorithms to identify patients using Electronic Health Records (EHR) and to build a repository "symptom checkers" for patients and healthcare providers. S4C will design an equitable, ethical, and sustainable framework for genetic newborn screening and new digital tools, corroborated by a large workout where legal, ethical, and social complexities will be addressed with the intent of making the framework highly and flexibly translatable into the diverse European health systems.
Identifiants
pubmed: 37992053
doi: 10.1371/journal.pone.0293503
pii: PONE-D-23-26393
pmc: PMC10664952
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293503Informations de copyright
Copyright: © 2023 Garnier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
none.
Références
Orphanet J Rare Dis. 2022 Jun 18;17(1):233
pubmed: 35717227
Am J Hum Genet. 2019 Jan 3;104(1):76-93
pubmed: 30609409
Lancet Reg Health Eur. 2022 Jan 28;13:100311
pubmed: 35199083
Nat Rev Drug Discov. 2011 May;10(5):341-9
pubmed: 21532564
Orphanet J Rare Dis. 2022 Apr 12;17(1):163
pubmed: 35414039
Bull World Health Organ. 2008 Apr;86(4):317-9
pubmed: 18438522
Eur J Hum Genet. 2020 Feb;28(2):165-173
pubmed: 31527858
Front Med (Lausanne). 2021 Feb 02;8:593281
pubmed: 33604345
Nat Protoc. 2022 Jun;17(6):1415-1443
pubmed: 35411044
Orphanet J Rare Dis. 2018 Nov 6;13(1):196
pubmed: 30400963
Rare Dis. 2013 Jan 28;1:e23579
pubmed: 25002987
Nat Rev Drug Discov. 2020 Feb;19(2):77-78
pubmed: 32020066
J Allergy Clin Immunol. 2021 Feb;147(2):428-438
pubmed: 33551024